Is Halozyme Therapeutics (HALO) Offering Value After Mixed Multi Year Share Price Performance [Yahoo! Finance]
Halozyme Therapeutics, Inc. (HALO)
Last halozyme therapeutics, inc. earnings: 2/24 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
halozyme.com/investors/default.aspx
Company Research
Source: Yahoo! Finance
If you are wondering whether Halozyme Therapeutics at around US$68.41 is offering good value or asking too much, you are not alone. The share price performance has been mixed recently, with a 1.6% return over 7 days, 7.9% over 30 days, a 2.7% decline year to date, and a 17.5% return over the past year, alongside a 103.8% return over 3 years and 33.8% over 5 years. Recent coverage has focused on how Halozyme Therapeutics fits into broader biotech themes and how its partnerships and product portfolio frame expectations for future performance. This context helps explain why the stock has shown both shorter term swings and stronger multi year returns. Right now, Halozyme Therapeutics has a valuation score of 3 out of 6 . The rest of this article will walk through the main valuation approaches behind that score and will point to a more complete way to think about value at the end. Find out why Halozyme Therapeutics's 17.5% return over the last year is lagging behind its peers. A
Show less
Read more
Impact Snapshot
Event Time:
HALO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HALO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HALO alerts
High impacting Halozyme Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
HALO
News
- Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ TechnologyPR Newswire
- How The Investment Story Is Shifting For Halozyme Therapeutics (HALO) After Recent Analyst Calls [Yahoo! Finance]Yahoo! Finance
- Halozyme Therapeutics (HALO) Appoints Interim CFO Amid Growth Plans [Yahoo! Finance]Yahoo! Finance
- Halozyme Therapeutics Touts $1.8B Revenue Outlook, ENHANZE Royalties and New Hypercon Deals at Conference [Yahoo! Finance]Yahoo! Finance
- Halozyme Names Interim CFO As Investors Weigh Valuation And Recent Weakness [Yahoo! Finance]Yahoo! Finance
HALO
Earnings
- 2/17/26 - Miss
HALO
Sec Filings
- 4/7/26 - Form 4
- 4/2/26 - Form 4
- 4/2/26 - Form 4
- HALO's page on the SEC website